Pharvaris

📍 Zug, Switzerland🗓 Founded 2015👥 75 employees💰 Last funded Sep 2019
Pharmaceutical Manufacturing🌐 pharvaris.com
Website LinkedIn
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
4
Total investors
3
Early stage
1
Mid stage
0
Late stage
2015
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Netherlands
2
Belgium
1
United States
1
Investor activity2015–2019 · investors recorded per year
201512016220191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Pharvaris?
Pharvaris has 4 investors on record on gritt.io, including 3 early-stage backers, 1 mid-stage.
When did Pharvaris last raise funding?
The most recent investment in Pharvaris recorded on gritt.io was in September 2019.
When was Pharvaris founded?
Pharvaris was founded in 2015.
What industry is Pharvaris in?
Pharvaris operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Pharvaris based?
Pharvaris is headquartered in Zug, Switzerland.